Loading…
GESA Pharmaceuticals (ჯი-ი-ეს-ეი ფარმაცევტიკალს) — a Georgian pharmaceutical import/representation company inferred from its high, stable margins (gross ~40%, net ~30–46%). Active and growing (revenue ~GEL 3.5m in 2020 to ~GEL 5.7m in 2024). Note: its asset base (~GEL 13.5m) far exceeds revenue, suggesting accumulation of non-operating assets/investments — treat balance-sheet ratios with care.
| Line item | 2020 | 2021 | 2022 | 2023 | 2024 | CAGR |
|---|---|---|---|---|---|---|
| Total Revenue | 3,472 | 5,854 | 7,206 | 5,524 | 5,654 | +13.0% |
| Total COGS | 2,038 | 3,909 | 4,447 | 3,319 | 2,863 | +8.9% |
| Gross Profit | 1,434 | 1,945 | 2,759 | 2,205 | 2,791 | +18.1% |
| Gross Margin | 41.3% | 33.2% | 38.3% | 39.9% | 49.4% | |
| 44 | 46 | 72 | 541 | 54 | +5.3% | |
| EBITDA | 1,390 | 1,899 | 2,687 | 1,663 | 2,737 | +18.5% |
| EBITDA Margin | 40.0% | 32.4% | 37.3% | 30.1% | 48.4% | |
| Total D&A | 0 | 0 | 0 | 0 | 0 | |
| EBIT / Operating Income | 1,390 | 1,899 | 2,687 | 1,663 | 2,737 | +18.5% |
| Total Interest Expense | 0 | 0 | 0 | 17 | 16 | -10.1% |
| 96 | 129 | 0 | 1 | 100 | nmf | |
| Profit Before Tax | 1,487 | 2,028 | 2,687 | 1,645 | 2,621 | +15.2% |
| Total Income Tax | 0 | 0 | 0 | 0 | 0 | |
| Net Profit / (Loss) | 1,487 | 2,028 | 2,687 | 1,645 | 2,621 | +15.2% |
| Net Margin | 42.8% | 34.6% | 37.3% | 29.8% | 46.4% |
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set.